ArticleCureus2026
Anesthetic Management of a Patient With Factor XIII Deficiency Undergoing Encephaloduroarteriosynangiosis (EDAS): A Case Report and Literature Review.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anesthetic Management for Encephaloduroarteriosynangiosis in Moyamoya Disease: A Hemodynamic and Neuromonitoring-Integrated Framework.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Factor XIII (FXIII) deficiency is an extremely rare inherited coagulopathy that poses significant perioperative risks of delayed bleeding despite normal routine coagulation tests. Due to the routine normality of the standard coagulation screening tests in the affected patients, the diagnosis needs a high index of clinical suspicion. The implications for the perioperative environment are especially critical in neurosurgical procedures, in which uncontrolled hemorrhage can lead to either stroke, irreversible neurological damage, or death. We discuss the case of a 48-year-old woman with FXIII deficiency and Moyamoya disease who has undergone left-sided encephaloduroarteriosynangiosis (EDAS) surgery after receiving 40 units/kg of plasma-derived FXIII concentrate (Corifact®). Normotension and normocapnia were ensured intraoperatively, and estimated blood loss was 300 milliliters. The hemoglobin levels were stable. The patient was discharged on day 3 after the surgery without any hemorrhagic incidents. We also surveyed the literature on FXIII deficiency in the perioperative environment that has been published so far, especially on diagnostic methods, replacement, and the findings in the neurosurgical patients. Given the limited literature on FXIII deficiency in the context of EDAS and Moyamoya disease, this report contributes valuable clinical insight and supports the need for individualized, evidence-based perioperative strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.